Jacob Laubach, MD
Harvard Medical School
Clinical Director of the Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Dr. Jacob Laubach completed his medical degree, residency, and fellowship in hematology at Duke University Medical Center in Durham, North Carolina. He is an Assistant Professor in Medicine at Harvard Medical School, and the Clinical Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston.
Since joining the Dana-Farber Cancer Institute faculty, Dr. Laubach has dedicated himself to the growth and expansion of the multiple myeloma clinical program and the advancement of clinical research evaluating new therapeutic agents in multiple myeloma. As a clinician, he has developed a large academic practice focused on the care of patients with plasma cell disorders, including multiple myeloma, AL amyloidosis, POEMS syndrome, and cryoglobulinemia. As a clinical investigator, his research has focused primarily on the development of new therapeutic agents. Dr. Laubach has been integrally involved in the study of histone deacetylase inhibition as a treatment strategy in multiple myeloma and in the development of monoclonal antibodies targeting myeloma tumor cell epitopes such as CS-1 (elotuzumab) and CD38 (daratumumab).